An observational study in Neurofibromatosis 1 and Plexiform Neurofibroma, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Recruiting at 5 sites in China. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Observational
Background/Rationale: Neurofibromatosis type 1 (NF1) affects about 1 in every 3000 people worldwide. Globally, 30\~50% NF1 patients will develop plexiform neurofibromas (PNs), which grow rapidly in early childhood and can cause disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment and bladder and bowel dysfunction. This systemic disease imposes a heavy psychosomatic and financial burden on patients and their caregivers. In NF1 patients, the lifetime risk of MPNST developed from PN is 8% to 13%. The mean age for NF1-associated death was approximately 20 years lower than that for the general population. Limited epidemiological and clinical data of Chinese NF1 patients is available to date. And the treatment pattern of Chinese NF1-PN patients is also unknown.
Objectives and Hypotheses: It is a descriptive study without formal hypothesis. The primary objective of this study is determining the percentage of NF1 patients who develop PN. The secondary objectives of this study include describing the clinical characteristics, tumor progression and treatment pattern of NF1-PN. The exploratory objective is exploring the epidemiological characteristics of other NF1 manifestations.
Methods:
Study design: The study is a retrospective multi-center chart review study. Data Source(s): All the data will be collected by CRF from inpatient and outpatient electronic medical records in every study site from January 1, 2019 to December 31, 2022.
Study Population: Patients who attended the study sites between January 1, 2019 - December 31, 2022 and were diagnosed with NF1 were included in this study. Statistical Analysis: This study is purely descriptive without any formal hypotheses.
Missing data for baseline characteristics will be assessed and addressed as a categorical variable with a level for missingness. All reported measures will be summarized in the study tables. Point estimates and their 95% CIs will be presented in the final analyses.
176 studies on the registry are indexed under Neurofibromatosis 1; 43 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 188 across 58 observational studies indexed under Neurofibromatosis 1.
Browse Neurofibromatosis 1 studies →Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University is the lead sponsor of 164 studies on the registry; 73 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients will be included in this study if they: 1) attended the study sites between January 1, 2019 and December 31, 2022; 2) were diagnosed with NF1 based on NIH NF1 consensus (Version 1987 or Version 2021); and 3) were not diagnosed with other malignant tumors from 2019.1.1 to 2022.12.31. As this study was a chart review, there was no systematic follow-up. Follow-up was based on individual patient needs, was not dictated by the study, and varied from person to person in a manner reflective of real clinical practice. Thus, patients were followed up until end of data availability, death, or loss of follow up, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study is purely descriptive study.
Determine the percentage of NF1 patients developed PN at the baseline.
The clinical diagnosis of PN mainly depends on the clinical manifestations and imaging of NF1 patients. Superficial PN has a clear clinical manifestation. It refers to a proliferation of cells in the nerve sheath which involves multiple nerve fascicles, forming a large pendulous mass with skin pigmentation on the surface. PN in vivo often has no significant clinical features and requires imaging examination, like MRI. Patients diagnosed with PN are recorded with the text of plexiform neurofibromas in the chart. The percentage of patients diagnosed with PN with imaging and the percentage of patients diagnosed with PN without imaging will be calculated.
Time frame: 2022.12.31
Clinical characteristics of NF1-PN:
Describe the percentage of symptomatic NF1-PN at the baseline.
Time frame: 2022.12.31
Tumor progression of NF1-PN
Describe the 1-year/2-year/3-year progression-free survival (PFS) rate of NF1- PN.
Time frame: 2022.12.31
Treatment pattern of NF1-PN:
Describe the percentage of NF1-PN patients underwent surgeries after index date.
Time frame: 2022.12.31
The exploratory endpoints:
Epidemiological characteristics of other NF1 manifestations: Describe the percentage of NF1 patients with cNF at the baseline.
Time frame: 2022.12.31
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2019 to primary completion in Dec 2022, 47 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University →